Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Net Cash Flow (2016 - 2025)

Jaguar Health (JAGX) has disclosed Net Cash Flow for 11 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 155.85% to $1.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$9.5 million, a 195.17% decrease, with the full-year FY2024 number at $1.6 million, up 61.12% from a year prior.
  • Net Cash Flow was $1.6 million for Q3 2025 at Jaguar Health, up from -$3.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $24.2 million in Q1 2021 to a low of -$19.5 million in Q3 2021.
  • A 5-year average of -$163315.8 and a median of -$332000.0 in 2021 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: plummeted 2071.99% in 2022, then soared 1848.57% in 2023.
  • Jaguar Health's Net Cash Flow stood at $4.7 million in 2021, then plummeted by 210.05% to -$5.1 million in 2022, then surged by 162.16% to $3.2 million in 2023, then tumbled by 262.89% to -$5.2 million in 2024, then skyrocketed by 130.13% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Net Cash Flow are $1.6 million (Q3 2025), -$3.5 million (Q2 2025), and -$2.4 million (Q1 2025).